Tvardi Threrapeutics' CEO on targeting STAT3
Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3 and avoid toxicity issues.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
Popular
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square
bottom of page